Thyroid, Papillary Carcinoma, Early
- Author: Eric J Lentsch, MD; Chief Editor: Arlen D Meyers, MD, MBA more...
Much attention has been generated regarding the topic of thyroid neoplasia and papillary thyroid carcinoma. This attention can be attributed to the frequency of benign thyroid nodules and the clinical difficulty in distinguishing these nodules from malignant thyroid lesions.
History Of The Procedure
Theodor Billroth, who performed many thyroidectomies in the mid-1800s, was the first to observe side effects of total thyroidectomy in the form of postoperative cretinoid changes. He noticed his patients became sluggish, fat, cold, and even mentally deranged, a condition that would later be termed myxedema.
Thyroidectomy began to be used in the treatment of toxic goiters in 1907. Prior to this point, the surgery was used to treat nontoxic goiters, with toxic goiter patients considered poor surgical candidates. Radioactive iodine was introduced as a therapeutic intervention in 1942 by Means, Evans, and Hertz. This was followed by the introduction of thiouracil, in 1943, by Edwin Bennet Astwood.
Landmark innovations in many disciplines, particularly in anesthesia, physiology, and radiology, as well as in methods of hemostasis and antisepsis, contributed to the development of the surgical treatment of thyroid disease. Technologic innovations, such as video-assisted thyroidectomy, have further contributed to making these operations safer .
Thyroid nodules are found in up to 7% of the population. Only 4-6.5% of these nodules are malignant. Malignant tumors of the thyroid account for only about 1% of all cancers and only 0.4% of cancer-related deaths. The prognosis for papillary thyroid carcinoma is favorable; however, controversy exists regarding management of this cancer. Surgery is the primary mode of therapy for treatment, but the most appropriate type of resection for this disease is controversial. Open and minimally invasive procedures are illustrated below.
Papillary thyroid carcinoma accounts for about 80% of all thyroid carcinomas in the United States. According to the American Cancer Society, thyroid cancer is the nation's most rapidly increasing cancer; it was estimated that about 64,300 new cases would be diagnosed in 2016.
The incidence of thyroid cancer has nearly tripled since the late 20th century, growing from 4.9 cases per 100,000 in 1975 to 14.3 cases per 100,000 in 2009 (a 2.9-fold increase). Virtually the whole increase has been due to a rise in the incidence of papillary thyroid cancer, from 3.4 to 12.5 cases per 100,000 (a 3.6-fold increase).
Despite the growth in the incidence of thyroid cancer, the disease's mortality rate has remained the same (0.5 deaths per 100,000). Between 1988 (the first year the Surveillance, Epidemiology, and End Results [SEER] program collected data on tumor size) and 2002, 49% of the increase in thyroid cancer was attributable of tumors measuring 1 cm or smaller.
These trends, combined with the known existence of a substantial reservoir of subclinical cancer and stable overall mortality, have suggested that the rise in thyroid cancer's incidence has reflected increased detection of subclinical disease. Nonetheless, although controversy exists, there is growing evidence that the expanded incidence of reported thyroid cancer may be due to an increase in new cases.
Thyroid cancer tumors most often occur in individuals aged 20-50 years. In adults, the female-to-male ratio of clinically diagnosed papillary carcinoma of the thyroid is 3:1; in children, the tumor is distributed nearly equally by sex. Although this condition is more common in females, they have a better overall prognosis. Papillary thyroid carcinoma occurs more often in whites than in blacks.
The etiology of papillary carcinoma has yet to be elucidated, but a number of associations have been made. Multiple genetic and epigenetic mutations result in the activation of signaling pathways that precipitate thyroid cancer. Common mutations include point mutations of the BRAF and RAS genes and chromosomal rearrangements of RET/PTC and PAX8/PPARG.
Moreover, research indicates that a link exists between higher body mass index (BMI) and greater tumor size, extrathyroidal invasion, and advanced tumor, node, metastasis (TNM) staging.
Activation of receptor tyrosine kinases (RET/PTC, TRK, MET), whether by rearrangement or gene amplification, appears to be specific for the transformation of thyroid follicular cells into papillary thyroid carcinomas. Often associated with exposure to ionizing radiation, these rearrangements produce chimeric proteins with tyrosine kinase activities that contribute to the development of the malignant phenotype. Approximately 40% of adults with sporadic papillary carcinoma have RET gene rearrangement, and about 15% have NTRK1 rearrangement. This rearrangement is higher (60%) in children.
Somatic point mutation in the BRAF gene may be the most common mutation among papillary thyroid cancers. Considered to be a poor prognostic marker, it varies from 29-69% in different series. This gene encodes a serine/threonine kinase acting on the RAS-RAF-MEK-MAPK signaling pathway. BRAF mutations seem to be much less common in childhood thyroid carcinomas. Identification of the BRAF mutation is making inroads into clinical practice as a diagnostic tool for the management of papillary thyroid cancers.
A 10-fold increased risk of thyroid cancer in relatives of patients with thyroid cancer suggests a genetic basis for susceptibility to these tumors. A correlation between papillary thyroid carcinoma and human leukocyte antigen (HLA)-DR7 has also been observed. Also, a parallel incidence has been described for this tumor in monozygotic twins.
Papillary thyroid cancer has been induced in animals with the administration of excess iodine. In Vienna, Austria, during a period when iodide intake was low in the population, papillary carcinoma accounted for only 25% of all thyroid cancers instead of the expected 80%.
In areas where goiters are endemic, the addition of iodine to the diet has increased the proportion of papillary carcinomas relative to follicular thyroid cancer. However, these cancers are less aggressive and have a better prognosis for long-term survival.
While iodine excess has been linked to point mutations, however, a study of post-Chernobyl thyroid cancer indicated that an association exists between RET/PTC chromosomal rearrangements and iodine deficiency. Conversely, excess iodine has been shown to have an antioncogenic role during RET/PTC3 oncogene activation. Studies have demonstrated a decreased papillary thyroid carcinoma rate in radiation-exposed regions where populations have an iodine-rich diet.
External radiation to the neck increases the incidence of papillary carcinoma of the thyroid later in life. Irradiation during childhood has been associated with the greatest risk for acquiring papillary thyroid cancer. As many as 9% of children irradiated for conditions such as tonsillar hypertrophy, thymic enlargement, and acne have developed thyroid cancer over a period of 20 years. Of the survivors of the atomic bomb explosions in Japan, 6.7% developed papillary thyroid cancers.
This percentage is much higher than what is expected in the general population. More recently, data have become available from studies of over 4000 people who developed thyroid cancer after the Chernobyl nuclear accident in 1986. They revealed that radiation exposure during childhood carries an increased risk of thyroid cancer and that the risk is radiation dose dependent. The youngest children are most sensitive to radiation-induced carcinogenesis, and the minimal latent period for thyroid cancer development after exposure is as short as 4 years. The vast majority of these cancers are papillary carcinomas. On the molecular level, chromosomal rearrangements (such as RET/PTC) are more common than point mutations of BRAF and other genes.
Most studies have found that radiation exposure increases the risk of developing thyroid cancer without affecting the patient's prognosis or the aggressiveness of the tumor. Some studies, however, have suggested that radiation may induce a more aggressive course. While treatment with radioactive iodine has not been shown to raise the incidence of thyroid cancers, a meta-analysis demonstrated an increase in the risk of thyroid, kidney, and stomach cancer at diagnostic doses of greater than 1 Gy.
Papillary carcinomas can range in size from microscopic, clinically undetectable lesions to masses of up to 10 cm in diameter. The average tumor size at diagnosis is 2.3 cm. Up to 75% of these tumors are multifocal within the thyroid. Most are pale and firm on gross examination; less than 10% of papillary carcinomas are truly encapsulated, with larger nodules usually unencapsulated and locally invasive. Penetration of the capsule of the thyroid gland occurs in about 40% of cases.
Well-differentiated thyroid carcinomas are the most common types of thyroid carcinoma. These include papillary and follicular thyroid carcinomas. Both arise from the endodermally-derived follicular cells that synthesize thyroxine and thyroglobulin. This is in contrast to medullary thyroid carcinoma, which is derived from the neuroendocrine calcitonin-producing parafollicular C cells of the thyroid.
Papillary tumors can have pure papillary histopathology, but more than one half contain an admixture of follicular elements. Regardless of the precise proportions, all neoplasms containing some papillary areas have identical biologic behavior; therefore, they are classified under the papillary, rather than the follicular, carcinomas.
The histopathologic diagnosis of follicular variant of papillary thyroid carcinoma (FVPCA) can be difficult. Lloyd (2004) examined interobserver variation by 10 experienced thyroid pathologists in the diagnosis of FVPCA in 87 tumors. A concordant diagnosis of FVPCA was made by all 10 reviewers with a cumulative frequency of 39%. Diagnostic criteria used to diagnose FVPCA, including pseudoinclusions, nuclear grooves, and powdery nuclei, are clearly not uniformly recognized, even by experts. Immunohistochemical markers, such as single nucleotide polymorphisms and messenger ribonucleic acid (mRNA) expression of VEGF-A, are being shown to provide more objective diagnostic criteria.[13, 14]
Initially, the immunohistochemical expression of cytokeratin 19, galectin-3 and HBME-1, 3 malignancy-related markers in thyroid papillary carcinoma, including its follicular variant, was used with caution.[15, 16] However, a study by de Matos et al found that these biomarkers can be used to accurately diagnose malignant and benign lesions both preoperatively and postoperatively.
Thus, genetic alterations in papillary carcinoma of the thyroid may hold the ultimate key to diagnosis. Three genetic alterations, including BRAF point mutations, RET/PTC rearrangements, or RAS point mutations, have been recognized in this regard. In a study by Adeniran (2006), these alterations have been shown to be associated with distinct microscopic, clinical, and biologic features of thyroid papillary carcinomas. BRAF mutations were associated with older age, taller cell appearance, and more advanced tumor stage at presentation. RET/PTC rearrangements presented at a younger age, showed typical papillary histology, and were associated with a high rate of lymph node metastases. Tumors with RAS mutations were exclusively of FVPCAs.
The identification of these alterations has increasingly led to the diagnostic and prognostic use of genetic studies in papillary thyroid carcinoma. Several genetic panels have been developed to identify genes specific to thyroid cancer and are now in clinical use.[19, 20] These involved genes may also serve as targets for cancer chemotherapy in patients in whom standard thyroid cancer treatment has not been effective.
The histologic features of papillary carcinoma of the thyroid include branching papillae composed of a central fibrovascular core and a single or stratified lining of cuboidal to columnar cells. Tumor cells may form colloid-containing follicles, and foci of squamous metaplasia are frequently found. Nuclear atypia is also an important diagnostic feature.
In more than half of these tumors, the nuclei have a characteristic ground-glass appearance; laminated calcific spherules known as psammoma bodies are also often found within the histological framework. In fact, the presence of psammoma bodies is virtually diagnostic for papillary carcinoma because they are rarely found in other lesions.
Papillary thyroid carcinomas typically invade the lymphatics and spread to other sites within the thyroid gland, as well as to the regional lymph nodes. Lymph node metastases have been reported in the range of 46-90% of cases of papillary carcinoma. Vascular invasion is uncommon; however, if it does occur, the spread of tumor is usually to the lungs and bones. Direct extension into the soft tissues of the neck occurs in approximately 25% of cases.
The variants of papillary thyroid carcinoma include the following:
Encapsulated tumors: About 10% of papillary carcinomas are completely surrounded by a dense fibrous capsule; the prognosis for patients with such tumors is better than the prognosis for patients with unencapsulated papillary carcinoma
Diffuse sclerosing variant: Occurring at a younger age, the diffuse sclerosing variant constitutes 2% of papillary carcinomas and may cause a diffuse goiter without palpable nodules that can be mistaken for goitrous autoimmune thyroiditis; diffuse involvement of one or both lobes occurs with dense sclerosis, patchy lymphocytic infiltration, and abundant psammoma bodies; prognosis for individuals with the diffuse sclerosing variant is less favorable than that for individuals with typical papillary thyroid carcinoma
Oxyphilic (Hürthle) cell type: The oxyphilic (Hürthle) cell type variant has typical papillary architecture but may be more aggressive than usual papillary carcinoma
Follicular variant: The follicular variant has a purely follicular architectural pattern but may be recognized by the typical cellular features of papillary carcinoma
Tall cell carcinoma: Tall cell carcinoma is a more aggressive form of thyroid carcinoma that differs from the usual form by showing tall columnar cells; the frequency of more aggressive behavior is higher, but the carcinoma resembles papillary carcinoma in other morphologic and clinical aspects
Columnar cell carcinoma: Columnar cell carcinoma is a distinctly more aggressive form of papillary thyroid carcinoma that occurs more often in older men and is associated with a poor prognosis
Solid cell variant: The lesion is made up of sheets of tumor cells that have the cytologic features of typical papillary thyroid carcinoma; about one third of cases exhibit vascular invasion and extrathyroidal extension; the tumors arise more often in pediatric patients with a history of radiation exposure 
Papillary thyroid carcinoma with prominent hobnail features: Research indicates that usually more than 30% of the tumor has hobnail features; a small percentage of these lesions have been found to have tall cell and diffuse sclerosing patterns; the carcinomas are very aggressive, with mortality from metastatic papillary thyroid carcinoma reported in 50% of cases 
The mainstays of the preoperative diagnosis of papillary carcinoma are a thorough history and physical examination, including an assessment of risk factors, along with ancillary tests such as cervical ultrasonography and aspiration cytology.
The most common presentation of thyroid cancer is a nontender palpable nodule. However, a diagnostic dilemma is present as this is the presentation of most benign thyroid conditions. A palpable nodule occurs in up to 7% of the general female population. A single nodule has a 5-12% malignancy rate, while multiple nodules have a 3% malignancy rate in the general population.
Papillary carcinoma may also present as a nodule with enlarged cervical lymph nodes or cervical lymphadenopathy in the absence of a palpable thyroid nodule. Benign thyroid tissue can be found in the neck anywhere medial to the sternocleidomastoid muscle. Any thyroid tissue lateral to the sternocleidomastoid muscle should be considered malignant.
Unlike follicular thyroid carcinoma, distant metastases of papillary thyroid carcinoma are rarely observed at the time of presentation. When distant metastases are present at the time malignancy is discovered, the primary tumor is almost invariably large and easily palpable.
During routine physical examination or ultrasonography, symptoms of dysphagia, odynophagia, or shortness of breath may lead to the discovery of a thyroid mass. The presence of a mass in the thyroid requires further investigation, especially in high-risk patients.
Lobectomy is indicated in patients who have isolated, indeterminate, solitary nodules who prefer a more limited surgical procedure. Lesions of less than 1 cm that are low-risk, unifocal, or intrathyroidal in the absence of prior head and neck irradiation can also qualify for lobectomy. Total thyroidectomy is indicated for the following:
Lesions of greater than 1 cm
Indeterminate nodules that have large tumors (>4 cm) with atypia on biopsy
Biopsy readings that are suspicious for papillary carcinoma
Patients with a family history of thyroid carcinoma
Patients with a history of radiation exposure
Patients with indeterminate nodules who have bilateral nodular disease 
In patients with clinically involved central or lateral neck lymph nodes, total thyroidectomy should be accompanied by clearance of the central neck of disease by therapeutic central-compartment (level VI) neck dissection. If the central neck lymph nodes are clinically uninvolved, patients with papillary thyroid carcinoma can still undergo prophylactic, ipsilateral or bilateral central-compartment neck dissection. However, in patients with small (T1 or T2), noninvasive papillary thyroid cancer that is clinically node-negative, thyroidectomy without central neck dissection may be appropriate.
Lateral neck compartmental lymph node dissection is indicated when there is biopsy-proven metastatic lateral cervical lymphadenopathy.
Knowledge of the anatomy of the infrahyoid neck and thyroid region aids in the identification and preservation of structures (eg, recurrent laryngeal nerve, superior laryngeal nerve, superior thyroid artery, inferior thyroid artery). The isthmus of the thyroid usually overlies the third tracheal ring, although this middle portion of the gland may be absent altogether in some individuals. The thyroid gland consists of a superior pole that may extend as far as the oblique line of the thyroid cartilage, and an inferior pole that may extend as far as the sixth tracheal ring.
The external branch of the superior laryngeal nerve innervates the cricothyroid muscle near the superior pole. The left recurrent laryngeal nerve lies in the tracheoesophageal groove, while the right recurrent laryngeal nerve approaches the thyroid gland from a more lateral position. The superior thyroid artery is the first branch of the external carotid artery and often accompanies the external laryngeal branch of the superior laryngeal nerve near the superior pole of the thyroid as it runs superficially toward the isthmus. The inferior thyroid artery arises from the thyrocervical trunk, which comes off of the subclavian artery. This artery runs in the tracheoesophageal groove and sends branches to the posterior aspect of the lateral thyroid lobe. The inferior thyroid artery has a longitudinal branch that anastomoses with the superior thyroid artery near the superior pole.
Surgical excision of papillary thyroid carcinoma has no absolute contraindications. Even people with distant metastasis would benefit from surgical removal of the primary disease, neck dissection, and ablation with iodine-131.
A total thyroidectomy may be contraindicated in people with disease limited to only one lobe of the thyroid who are likely to be noncompliant with thyroid replacement therapy. These individuals may be better suited for a hemithyroidectomy.
Dadan J, Nowacka A. A journey into the past--the history of thyroid surgery. Wiad Lek. 2008. 61(1-3):88-92. [Medline].
Cancer Facts & Figures 2016. American Cancer Society. Available at http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf. Accessed: 2016 Apr 6.
Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014 Apr 1. 140(4):317-22. [Medline].
Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011 Aug 30. 7(10):569-80. [Medline].
Kim HJ, Kim NK, Choi JH, Sohn SY, Kim SW, Jin SM, et al. Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clin Endocrinol (Oxf). 2013 Jan. 78(1):134-40. [Medline].
Leeman-Neill RJ, Brenner AV, Little MP, et al. RET/PTC and PAX8/PPAR? chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. Cancer. 2013 May 15. 119(10):1792-9. [Medline]. [Full Text].
Fiore AP, Fuziwara CS, Kimura ET. High iodine concentration attenuates RET/PTC3 oncogene activation in thyroid follicular cells. Thyroid. 2009 Nov. 19(11):1249-56. [Medline].
Nikiforov YE. Radiation-induced thyroid cancer: what we have learned from Chernobyl. Endocr Pathol. 2006 Winter. 17(4):307-17. [Medline].
Hieu TT, Russell AW, Cuneo R, et al. Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a meta-analysis. Endocr Relat Cancer. 2012 Oct. 19(5):645-55. [Medline].
Lloyd RV, Erickson LA, Casey MB, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004 Oct. 28(10):1336-40. [Medline].
Dardano A, Falzoni S, Caraccio N, et al. 1513A>C polymorphism in the P2X7 receptor gene in patients with papillary thyroid cancer: correlation with histological variants and clinical parameters. J Clin Endocrinol Metab. 2009 Feb. 94(2):695-8. [Medline].
Salajegheh A, Smith RA, Kasem K, et al. Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. Eur J Surg Oncol. 2011 Jan. 37(1):93-9. [Medline].
Sahoo S, Hoda SA, Rosai J, DeLellis RA. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol. 2001 Nov. 116(5):696-702. [Medline].
Papotti M, Rodriguez J, De Pompa R, Bartolazzi A, Rosai J. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol. 2005 Apr. 18(4):541-6. [Medline].
de Matos LL, Del Giglio AB, Matsubayashi CO, de Lima Farah M, Del Giglio A, da Silva Pinhal MA. Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol. 2012 Aug 13. 7:97. [Medline]. [Full Text].
Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006 Feb. 30(2):216-22. [Medline].
Fiore K. New Diagnostic Tool Ready for Prime Time in Thyroid Cancer. MedPage Today. Oct 22 2013. [Full Text].
Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013 Nov. 98(11):E1852-60. [Medline]. [Full Text].
Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 Nov. 19(11):1167-214. [Medline]. [Full Text].
[Guideline] Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association. Available at http://www.thyroid.org/thyroid-guidelines/revised/nodules/. Accessed: Dec 9 2014.
Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2009 Nov. 19(11):1159-65. [Medline].
de Geus-Oei LF, Pieters GF, Bonenkamp JJ, Mudde AH, Bleeker-Rovers CP, Corstens FH, et al. 18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med. 2006 May. 47(5):770-5. [Medline].
Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008 Mar. 49(3):480-508. [Medline].
Frilling A, Tecklenborg K, Görges R, Weber F, Clausen M, Broelsch EC. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg. 2001 Dec. 234(6):804-11. [Medline]. [Full Text].
Lang BH. The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Prognostication, Diagnosis, and Management of Thyroid Carcinoma. J Thyroid Res. 2012. 2012:198313. [Medline]. [Full Text].
Vorländer C, Wolff J, Saalabian S, Lienenlüke RH, Wahl RA. Real-time ultrasound elastography--a noninvasive diagnostic procedure for evaluating dominant thyroid nodules. Langenbecks Arch Surg. 2010 Sep. 395(7):865-71. [Medline].
Xing P, Wu L, Zhang C, et al. Differentiation of benign from malignant thyroid lesions: calculation of the strain ratio on thyroid sonoelastography. J Ultrasound Med. 2011 May. 30(5):663-9. [Medline].
Duntas LH, Cooper DS. Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. Thyroid. 2008 May. 18(5):509-16. [Medline].
Yamazaki CA, Padovani RP, Biscolla RP, Ikejiri ES, Marchetti RR, Castiglioni ML, et al. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma. Thyroid. 2012 Oct. 22(10):1002-6. [Medline].
Suman P, Wang CH, Abadin SS, et al. Timing of radioactive iodine therapy does not impact overall survival in high-risk papillary thyroid carcinoma. Endocr Pract. 2016 Mar 28. [Medline].
Miccoli P, Berti P, Materazzi G, et al. Minimally invasive video-assisted thyroidectomy: five years of experience. J Am Coll Surg. 2004 Aug. 199(2):243-8. [Medline].
Takami HE, Ikeda Y. Minimally invasive thyroidectomy. Curr Opin Oncol. 2006 Jan. 18(1):43-7. [Medline].
Caliceti U, Cavicchi O, Piccin O, Rinaldi Ceroni A. [Non-endoscopic minimally invasive thyroidectomy in papillary carcinoma. Our experience]. Suppl Tumori. 2005 May-Jun. 4(3):S157-8. [Medline].
DI JZ, Zhang HW, Han XD, Zhang P, Zheng Q, Wang Y. Minimally invasive video-assisted thyroidectomy for accidental papillary thyroid microcarcinoma: comparison with conventional open thyroidectomy with 5 years follow-up. Chin Med J (Engl). 2011 Oct. 124(20):3293-6. [Medline].
Miccoli P, Elisei R, Materazzi G, Capezzone M, Galleri D, Pacini F, et al. Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness. Surgery. 2002 Dec. 132(6):1070-3; discussion 1073-4. [Medline].
Lee S, Ryu HR, Park JH, Kim KH, Kang SW, Jeong JJ, et al. Early surgical outcomes comparison between robotic and conventional open thyroid surgery for papillary thyroid microcarcinoma. Surgery. 2012 May. 151(5):724-30. [Medline].
Nixon IJ, Ganly I, Patel SG, Palmer FL, Whitcher MM, Tuttle RM, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery. 2012 Apr. 151(4):571-9. [Medline].
Nixon IJ, Ganly I, Shah JP. Thyroid cancer: surgery for the primary tumor. Oral Oncol. 2013 Jul. 49(7):654-8. [Medline].
[Guideline] Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association. Available at http://www.thyroid.org/thyroid-guidelines/revised/longterm/. Accessed: Dec 24 2014.
McLeod DS, Sawka AM, Cooper DS. Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet. 2013 Mar 23. 381(9871):1046-57. [Medline].
[Guideline] Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association. Available at http://www.thyroid.org/thyroid-guidelines/revised/directions/. Accessed: Dec 24 2014.
Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S, et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol. 2004 Sep 1. 22(17):3531-9. [Medline].
Brzezinski J, Migodzinski A, Toczek A, Tazbir J, Dedecjus M. Patterns of cyclin E, retinoblastoma protein, and p21Cip1/WAF1 immunostaining in the oncogenesis of papillary thyroid carcinoma. Clin Cancer Res. 2005 Feb 1. 11(3):1037-43. [Medline].
Dagan T, Bedrin L, Horowitz Z, Chaushu G, Wolf M, Kronenberg J, et al. Quality of life of well-differentiated thyroid carcinoma patients. J Laryngol Otol. 2004 Jul. 118(7):537-42. [Medline].
Finley DJ, Arora N, Zhu B, Gallagher L, Fahey TJ 3rd. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab. 2004 Jul. 89(7):3214-23. [Medline].
Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf). 2004 Aug. 61(2):239-43. [Medline].
Johnson NA, Tublin ME. Postoperative surveillance of differentiated thyroid carcinoma: rationale, techniques, and controversies. Radiology. 2008 Nov. 249(2):429-44. [Medline].
Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer. 2005 Mar. 12(1):49-64. [Medline].
Mikosinski S, Pomorski L, Oszukowska L, et al. The diagnostic value of thyroglobulin concentration in fine-needle aspiration of the cervical lymph nodes in patients with differentiated thyroid cancer. Endokrynol Pol. 2006 Jul-Aug. 57(4):392-5. [Medline].
Salvatore B, Paone G, Klain M, et al. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation. Q J Nucl Med Mol Imaging. 2008 Mar. 52(1):2-8. [Medline].
Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery. 2006 Dec. 140(6):1000-5; discussion 1005-7. [Medline].
Tagay S, Herpertz S, Langkafel M, et al. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur J Endocrinol. 2005 Dec. 153(6):755-63. [Medline].
Zhau J, Hui Y, Wang Y, et al. Limitations of Integrated FDG PET/CT Imaging in Differentiation of Thyroid Malignancy from Benign Disease. J Nucl. Med. 2006. 47 (suppl.1):84.
Zou M, Famulski KS, Parhar RS, et al. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab. 2004 Dec. 89(12):6146-54. [Medline].
Zuijdwijk MD, Vogel WV, Corstens FH, Oyen WJ. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma. Nucl Med Commun. 2008 Jul. 29(7):636-41. [Medline].
|Younger Than 45 Years||Age 45 Years and Older|
|Stage I||Any T, Any N, M0||T1, N0, M0|
|Stage II||Any T, Any N, M1||T2, N0, M0|
|Stage III||T3, N0, M0, T1, T2, T3, N1a, M0|
|Stage IVa||T1, T2, T3, N1b, M0, T4a, N0, N1, M0|
|Stage IVb||T4b, any N, M0|
|Stage IVc||Any T, any N, M1|